BACKGROUND: Despite wide availability of treatment options for hepatocellular carcinoma (HCC), several studies have suggested underutilisation in clinical practice. AIMS: To quantify utilisation rates for HCC treatment among patients with HCC in the United States, and to summarise patterns of association between utilisation rates and patient socio-demographic characteristics. METHODS: We performed a systematic literature review using the Medline database from January 1989 to March 2013. Two investigators independently extracted data on patient populations, study methods and results using standardised forms. Pooled treatment rates for any treatment and curative treatment, with 95% confidence intervals, were calculated. Prespecified subgroup analysis was performed to identify patient-level correlates of treatment utilisation. RESULTS: We identified 24 studies that met inclusion criteria. The pooled rates of any treatment and curative treatment were 52.8% (95% CI 52.2-53.4%) and 21.8% (95% CI 21.4-22.1%) respectively. Among patients diagnosed at an early stage, the pooled curative treatment rate was 59.0% (95% CI 58.1-59.9%). Elderly, non-Caucasians and patients of low socioeconomic status had lower treatment rates than their counterparts. CONCLUSIONS: Rates of HCC treatment in the United States, including curative treatment rates among patients detected at an early stage, are disappointingly low. Future efforts should focus on identifying appropriate intervention targets to increase treatment rates and reduce socio-demographic disparities.
BACKGROUND: Despite wide availability of treatment options for hepatocellular carcinoma (HCC), several studies have suggested underutilisation in clinical practice. AIMS: To quantify utilisation rates for HCC treatment among patients with HCC in the United States, and to summarise patterns of association between utilisation rates and patient socio-demographic characteristics. METHODS: We performed a systematic literature review using the Medline database from January 1989 to March 2013. Two investigators independently extracted data on patient populations, study methods and results using standardised forms. Pooled treatment rates for any treatment and curative treatment, with 95% confidence intervals, were calculated. Prespecified subgroup analysis was performed to identify patient-level correlates of treatment utilisation. RESULTS: We identified 24 studies that met inclusion criteria. The pooled rates of any treatment and curative treatment were 52.8% (95% CI 52.2-53.4%) and 21.8% (95% CI 21.4-22.1%) respectively. Among patients diagnosed at an early stage, the pooled curative treatment rate was 59.0% (95% CI 58.1-59.9%). Elderly, non-Caucasians and patients of low socioeconomic status had lower treatment rates than their counterparts. CONCLUSIONS: Rates of HCC treatment in the United States, including curative treatment rates among patients detected at an early stage, are disappointingly low. Future efforts should focus on identifying appropriate intervention targets to increase treatment rates and reduce socio-demographic disparities.
Authors: C Cammà; V Di Marco; G Cabibbo; F Latteri; L Sandonato; P Parisi; M Enea; M Attanasio; M Galia; N Alessi; A Licata; M A Latteri; A Craxì Journal: Aliment Pharmacol Ther Date: 2008-03-27 Impact factor: 8.171
Authors: Victor Zaydfudim; Martin A Whiteside; Marie R Griffin; Irene D Feurer; J Kelly Wright; C Wright Pinson Journal: Ann Surg Oncol Date: 2010-06-29 Impact factor: 5.344
Authors: Linda L Wong; Brenda Hernandez; Sandi Kwee; Cheryl L Albright; Gordon Okimoto; Naoky Tsai Journal: Am J Surg Date: 2012-01-09 Impact factor: 2.565
Authors: Richard Todd Stravitz; Douglas M Heuman; Nisha Chand; Richard K Sterling; Mitchell L Shiffman; Velimir A Luketic; Arun J Sanyal; Adil Habib; Anastasios A Mihas; Ho-Chong S Giles; Daniel G Maluf; Adrian H Cotterell; Marc P Posner; Robert A Fisher Journal: Am J Med Date: 2008-02 Impact factor: 4.965
Authors: Richard S Hoehn; Dennis J Hanseman; Peter L Jernigan; Koffi Wima; Audrey E Ertel; Daniel E Abbott; Shimul A Shah Journal: HPB (Oxford) Date: 2015-09 Impact factor: 3.647
Authors: Amit G Singal; Akbar K Waljee; Nishant Patel; Emerson Y Chen; Jasmin A Tiro; Jorge A Marrero; Adam C Yopp Journal: J Natl Compr Canc Netw Date: 2013-09-01 Impact factor: 11.908
Authors: Manuel Hernández-Guerra; Alejandro Hernández-Camba; Juan Turnes; Luis Martin Ramos; Laura Arranz; José Mera; Javier Crespo; Enrique Quintero Journal: United European Gastroenterol J Date: 2015-06 Impact factor: 4.623
Authors: Nicole E Rich; Caitlin Hester; Mobolaji Odewole; Caitlin C Murphy; Neehar D Parikh; Jorge A Marrero; Adam C Yopp; Amit G Singal Journal: Clin Gastroenterol Hepatol Date: 2018-05-31 Impact factor: 11.382
Authors: Ali A Mokdad; Hong Zhu; Jorge A Marrero; John C Mansour; Amit G Singal; Adam C Yopp Journal: Am J Gastroenterol Date: 2016-05-10 Impact factor: 10.864
Authors: Amit G Singal; Jasmin A Tiro; Jorge A Marrero; Katharine McCallister; Caroline Mejias; Brian Adamson; Wendy Pechero Bishop; Noel O Santini; Ethan A Halm Journal: Gastroenterology Date: 2016-11-05 Impact factor: 22.682